Arcutis Biotherapeutics (ARQT) said Monday the US Food and Drug Administration cleared an expanded use of its Zoryve cream to treat plaque psoriasis in children as young as 2 years old.
The regulatory clearance extends the treatment option to younger patients from the previous age threshold of 6 years and older, the company said.
Health regulators based the decision on a 4-week evaluation study analyzing the medication in patients aged 2 to 5, Arcutis said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments